Bispecific Antibodies: New and Improved Anticancer Weapons?

Bispecific Antibodies: New and Improved Anticancer Weapons?

Posted by Leanne Kodsman on

While monoclonal antibodies are widely used for therapeutically and commercially, recent developments show that bispecific antibodies (bsAbs), or dual specificity antibodies, may be more successful as they are able to focus on two or more targets.

bsAbs can redirect immune effector cells to enhance tumor destruction. According to the GEN News article, "by targeting two different receptors in combination on the same cell, these antibodies can induce modifications of cell signaling, including the inactivation of proliferation or inflammatory pathways."


While monoclonal antibodies are widely used for therapeutically and commercially, recent developments show that bispecific antibodies (bsAbs), or dual specificity antibodies, may be more successful as they are able to focus on two or more targets.

bsAbs can redirect immune effector cells to enhance tumor destruction. According to the GEN News article, "by targeting two different receptors in combination on the same cell, these antibodies can induce modifications of cell signaling, including the inactivation of proliferation or inflammatory pathways."

With a cumulative value of 3.5 billion for six bispecific antibody deals in the past two years, this market is steadily growing and improving.

"Scientists at Genentech have developed an approach to production challenges posed by making an antibody with two or more specificities that are non-immunogenic and that retain Fc region functionality." GEN news writes.

This method is based on Genentech's own "knobs-into-holes" technology. Two antibodies are cultured into half expressed forms and then self-assemble after co-fermentation and co-purification.

For more on this subject, read the GEN News article.

Innovative Research sells many monoclonal and polyclonal antibodies that could be used in research like this.


    Innovative Research was established in 1998 after the realization that dependable, high-quality, and affordable research materials were hard to come by. Starting with core products like human plasma and serum, Innovative Research has grown to be a trusted supplier of all lab reagents, including human biologicals and ELISA kits. Today, we manufacture and supply thousands of high-quality human and animal biologicals including plasma, serum, tissues, and proteins.


Related Posts

Interview with Innovative Research CEO Donna Schelby
Earlier this month, Innovative Research CEO Donna Schelby sat down with Life Science Ma...
Read the Article
Innovative Research Partnership with BioscienceLA
Innovative Research has partnered with BioscienceLA, a nonprofit organization located i...
Read the Article
Donna Schelby Named as CEO of Innovative Research, Inc.
We are pleased to announce that Donna Schelby has been named as CEO of Innovative Resea...
Read the Article

← Older Post Newer Post →

×